Synerkine Pharma

Synerkine Pharma

Creating Innovative Pain Solutions

Founded 2018

The Netherlands 6 employees Series A Total: $12.10M Biotechnology, Health Care

Synerkine Pharma is a Dutch-based biotechnology startup that was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU). The company is dedicated to the development of novel fusion proteins, known as Synerkines, with a focus on creating innovative pain solutions. These fusion proteins leverage the immunoregulatory activity of different cytokines to modulate a broad number of targets, including key elements in the pain pathway. This approach provides treatment options for chronic pain conditions with a mechanism of action that sets them apart from current analgesic drugs. With a €5.30M Series A investment received on 12 October 2023 from a consortium of investors including InnovationQuarter, Thuja Capital, Utrecht Health Seed Fund, and Flerie Invest, Synerkine Pharma is well-positioned to advance its research and development efforts in the field of pain management. The company's unique fusion proteins and their potential in addressing unmet medical needs in chronic pain treatment have drawn significant attention from investors and the healthcare industry. By leveraging innovative biotechnological solutions, Synerkine Pharma aims to bring about a paradigm shift in pain management, offering a promising avenue for addressing the challenges associated with chronic pain conditions. As it moves forward with its endeavors, the company stands to make valuable contributions to the fields of biotechnology and healthcare, offering potential for therapeutic and commercial success in the years to come.

Funding Stage	Amount	Investors	Lead Investors	Date
Debt Financing	Undisclosed	1	Netherlands Enterprise Agency	12 Oct 2023
Series A	€5.30M	4	InnovationQuarter, Thuja Capital +2	12 Oct 2023
Series A	€3.50M	3	Thuja Capital, Utrecht Holdings +1	16 Dec 2021
Series A	€3.30M	1	Thuja Capital	25 Mar 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Debt Financing

Undisclosed

Netherlands Enterprise Agency

12 Oct 2023

Series A

€5.30M

InnovationQuarter, Thuja Capital +2

12 Oct 2023

Series A

€3.50M

Thuja Capital, Utrecht Holdings +1

16 Dec 2021

Series A

€3.30M

Thuja Capital

25 Mar 2019

FAQ About Synerkine Pharma

Creating Innovative Pain Solutions

Synerkine Pharma was founded in 2018.

Synerkine Pharma is headquartered in The Netherlands.

Synerkine Pharma operates in Biotechnology and Health Care. Its work centres on pharmaceuticals, pain management, innovation and fusion proteins.

Synerkine Pharma has approximately 6 employees.

Synerkine Pharma has completed 4 funding rounds, raising a total of $12.10M. The latest funding stage is Series A.

Top alternatives and competitors to Synerkine Pharma include Sarentis Therapeutics, Aegera Therapeutics Inc., Concortis Biosystems Corp, Initiator Pharma , Koutif Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Synerkine Pharma and Sarentis Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Synerkine Pharma

Funding Rounds & Investors (4)

Synerkine Pharma Alternatives & Competitors

FAQ About Synerkine Pharma